Brainstorm Cell Therapeutics Inc. (BCLI)

Overview

Brainstorm Cell Therapeutics Inc. is a pioneering entity in the biotechnology sector, focusing on the innovation and advancement of autologous cellular therapies aimed at the treatment of neurodegenerative diseases. Founded in the year 2000 and undergoing a name change from Golden Hand Resources Inc. to its current designation in November 2004, the enterprise is headquartered in New York, New York. Brainstorm Cell Therapeutics Inc. distinguishes itself through its proprietary cell therapy platform, NurOwn, which utilizes sophisticated cell culture techniques. This platform is dedicated to the cultivation of autologous bone marrow-derived mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic factors. These factors are crucial for modulating neuroinflammatory and neurodegenerative processes, fostering neuronal survival, and enhancing neurological functions across several conditions.

Products and Services

• NurOwn for Amyotrophic Lateral Sclerosis (ALS)

This is Brainstorm Cell Therapeutics Inc.'s leading product, having successfully completed a Phase III clinical trial. NurOwn for ALS showcases the company's commitment to addressing this challenging neurodegenerative disease by inducing MSCs to produce high levels of neurotrophic factors, thereby aiming to halt or reverse the disease's progression through the promotion of neuronal survival and improved neurological function.

• NurOwn for Progressive Multiple Sclerosis (MS)

Currently in a Phase II clinical trial, this application of the NurOwn technology exemplifies a novel approach to treating progressive MS. Similar to its application in ALS, NurOwn for MS leverages the potential of MSCs to secrete neurotrophic factors, targeting the modulation of the disease's inflammatory processes, and aiming to enhance the neurological capabilities of patients suffering from this form of multiple sclerosis.

• NurOwn for Alzheimer's Disease

As Alzheimer's disease represents one of the most prevalent and devastating forms of neurodegenerative diseases, Brainstorm Cell Therapeutics Inc. is extending its proprietary technology to combat this condition as well. Although specific trial phases are not mentioned, the application of NurOwn in Alzheimer's disease research underscores the company's broader commitment to tackling a wide range of neurodegenerative diseases by enhancing neuroprotection and functional neurological outcomes.

• NurOwn for Other Neurodegenerative Diseases

Besides ALS, MS, and Alzheimer's disease, Brainstorm Cell Therapeutics Inc. is exploring the potential applications of its NurOwn technology in addressing a broader spectrum of neurodegenerative diseases. This forward-thinking approach reflects the company's dedication to leveraging its cell therapy platform for the benefit of patients with various neurodegenerative conditions, aiming at significantly improving quality of life and functional outcomes.